Meta-Analysis
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2015; 21(22): 7022-7035
Published online Jun 14, 2015. doi: 10.3748/wjg.v21.i22.7022
Standard chemotherapy with cetuximab for treatment of colorectal cancer
Xin-Xiang Li, Lei Liang, Li-Yong Huang, San-Jun Cai
Xin-Xiang Li, Lei Liang, Li-Yong Huang, San-Jun Cai, Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Xin-Xiang Li, Lei Liang, Li-Yong Huang, San-Jun Cai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Author contributions: Li XX participated in data collection and analysis, and wrote the manuscript; Liang L and Huang LY participated in data collection and help to perform the statistical analysis; Cai SJ conceived of the study, participated in its design and provided the critical revision; all authors read and approved the final manuscript.
Conflict-of-interest: All the authors declare no conflicts of interest.
Data sharing: Technical appendix, statistical code, and dataset available from the corresponding author at cai_sanjunsci@163.com.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: San-Jun Cai, MD, Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai 200032, China. cai_sanjunsci@163.com
Telephone: +86-21-64085875 Fax: +86-21-64085875
Received: October 17, 2014
Peer-review started: October 19, 2014
First decision: December 2, 2014
Revised: December 12, 2014
Accepted: February 12, 2015
Article in press: February 13, 2015
Published online: June 14, 2015
Core Tip

Core tip: The addition of cetuximab to irinotecan containing chemotherapy regimen was sufficient to improve overall survival and progression-free survival in wild-type KRAS metastatic colorectal cancer patients, but not in patients with mutant-type KRAS.